Acumen Pharmaceuticals (ABOS) Amortizatization of Intangibles (2021 - 2026)
Acumen Pharmaceuticals recorded quarterly Amortizatization of Intangibles of -$25000.0 in Q1 2026, down 175.76% quarter-over-quarter from $33000.0 in Q4 2025, and down 183.33% year-over-year from $30000.0 in Q1 2025.
Acumen Pharmaceuticals' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at -$25000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 183.33% year-over-year to -$25000.0; the TTM figure through Mar 2026 stood at $71000.0 (down 97.84% YoY), while the FY2025 annual figure was $126000.0, down 97.49% from the prior year.
- Amortizatization of Intangibles came in at -$25000.0 for Q1 2026 at Acumen Pharmaceuticals, down from $33000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $4.9 million in Q4 2024 to a low of -$1.7 million in Q2 2024.
- A 5-year average of $455882.4 and a median of $33000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles surged 1919.32% in 2023 and tumbled 669.0% in 2024, its largest moves.
- Acumen Pharmaceuticals' Amortizatization of Intangibles stood at $88000.0 in 2022, then soared by 1919.32% to $1.8 million in 2023, then soared by 177.43% to $4.9 million in 2024, then plunged by 99.33% to $33000.0 in 2025, then plunged by 175.76% to -$25000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$25000.0, $33000.0, and $32000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -25,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25,000.00 |
| Mar 31, 2026 | -25,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 4.93 Mn |
| Dec 31, 2024 | 4.93 Mn |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | -1.71 Mn |
| Jun 30, 2024 | -1.71 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Sep 30, 2023 | 710,000.00 |
| Sep 30, 2023 | 710,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 334,000.00 |
| Mar 31, 2023 | 334,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Dec 31, 2022 | 88,000.00 |
| Sep 30, 2022 | -191,000.00 |
| Sep 30, 2022 | -191,000.00 |
| Jun 30, 2022 | -417,000.00 |
| Jun 30, 2022 | -417,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Dec 31, 2021 | -6,000.00 |